Enzyme Research journal publishes new peer-reviewed article involving Protandim
Published on June 4, 2011 at 2:55 AM
LifeVantage Corporation (OTCBB: LFVN), the maker of Protandim®, a clinically demonstrated, science-based therapy for the reduction of oxidative stress by the synergistic activation of Nrf2, announced today that a new peer-reviewed review article involving Protandim® was published in the scientific journal Enzyme Research
The review, conducted by researchers at Louisiana State University, examined the biochemical mechanisms that underlie the ability of Protandim® ,when ingested, to suppress tumors in mice. The ability discussed in this article was previously demonstrated by the authors in a study involving a mouse two-stage model of chemically-induced skin cancer. Protandim®, a patented dietary supplement comprised of five highly synergistic herbal ingredients, has been shown in earlier studies to activate the transcription factor Nrf2, a signal to the cell's DNA to regulate a network of protective genes. This review compares Protandim's® believed mechanism of action with information derived from similar complementary studies, which have also been aimed at the reduction of oxidative stress which is linked to many diseases including cancer. Even though results of certain animal testing do not translate into similar results for human subjects, this data is very promising in greatly reducing oxidative stress and may provide the same results in humans.
The authors conclude that oxidative stress forms a mechanistic linkage between cell proliferation, inflammation, and apoptosis, suggesting that potent multimodal antioxidant inducers may potentially be utilized with conventional chemotherapeutics. They note that efforts are currently underway to discover and develop compounds that effectively induce manganese superoxide dismutase (MnSOD) in hopes of incorporating antioxidant-based therapies into current clinical practice. They suggest that the development of various MnSOD inducers to be used during the early-onset of tumorigenesis may represent a plausible approach to suppress underlying mechanisms involved in carcinogenesis.
"This work was conceived, funded and created by investigators at the Louisiana State University Health Sciences Center at Shreveport, completely independent of LifeVantage," stated Douglas Robinson, LifeVantage CEO. "LifeVantage greatly appreciates the continuing academic interest in Protandim® shown by researchers such as Dr. Zhao and his colleagues. This scholarly contribution underscores the current value and future potential with which Protandim® is being viewed by the biomedical research community, particularly with regard to health conditions associated with oxidative stress."